
MC2-25-C1 new drug for uremic pruritus starts phase II clinical trial
On September 14, MC2 Therapeutics announced that it had completed the first patient dosing of the Phase II MC2-25-C1 trial. The trial was designed to
On September 14, MC2 Therapeutics announced that it had completed the first patient dosing of the Phase II MC2-25-C1 trial. The trial was designed to